Joe asked me how CYDY is doing considering their S
Post# of 36564
(Total Views: 437)
Posted On: 08/04/2021 10:52:57 PM
Joe asked me how CYDY is doing considering their SEC "investigation".
I'm not sure Joe but their breast cancer early treatment results are looking pretty darn good. Do we have a breast cancer study going on? Have we even enrolled anyone in 2021? If so, how many?
If so, how are our results vs these for leronlimab?
Triple Negative Breast Cancer – Leronlimab Plus Chemo Appears to Prolong Survival
August 4, 2021
Breast Cancer
Biological Drugs, Chemotherapy, Stage 4 Cancer
Straight to the Point in Triple Negative Breast Cancer
Leronlimab (PRO 140) has demonstrated promising preliminary results in a phase 1b/2 clinical trial (NCT03838367) for patients with metastatic triple negative breast cancer (mTNBC), according to a press release from drug company CytoDyn.
Patients who were given Leronlimab — an antibody blocking CCR5 receptor which is expressed on tumor cells – with Carboplatin experienced a 300% increase in mean time to disease progression, as well as a 450% increase in 1-year survival.
Leronlimab (PRO 140) is administered via injection.
About the Trial
This phase 1b-2 study included 30 patients with mTNBC. In the first stage, patients were divided into 3 experimental cohorts:
In cohort A, patients received 350 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort B treated patients with 525 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort C treated patients with 700 mg of Leronlimab weekly and Carboplatin every 3 weeks.
The trial enrolled patients over 18 years of age who had expression of CCR5 on their cancer cells by immunohistochemistry, IHC, test.
“We are very excited about these preliminary results and are eager to discuss the next regulatory steps based on [these] data,” Scott Kelly, MD, chief medical officer of CytoDyns and chairman of the board said in a press release. “Based on Leronlimab’s mechanism of action, we believe these results may provide tangible hope for patients suffering from mTNBC, and potentially other forms of cancer.”
What is the current status of Leronlimab (PRO140) in Triple Negative Breast Cancer?
The FDA has granted a Fast-Track designation to Leronlimab (PRO140) for use in combination with Carboplatin for the treatment of patients with CCR5-positive metastatic Triple Negative Breast Cancer, TNBC.
Take home message
Patients with metastatic Triple Negative Breast Cancer, TNBC, being treated with Leronlimab and Carboplatin have experienced an increase in survival.
Talk to us so see if we can help you to actually get the most advanced treatment.
I'm not sure Joe but their breast cancer early treatment results are looking pretty darn good. Do we have a breast cancer study going on? Have we even enrolled anyone in 2021? If so, how many?
If so, how are our results vs these for leronlimab?
Triple Negative Breast Cancer – Leronlimab Plus Chemo Appears to Prolong Survival
August 4, 2021
Breast Cancer
Biological Drugs, Chemotherapy, Stage 4 Cancer
Straight to the Point in Triple Negative Breast Cancer
Leronlimab (PRO 140) has demonstrated promising preliminary results in a phase 1b/2 clinical trial (NCT03838367) for patients with metastatic triple negative breast cancer (mTNBC), according to a press release from drug company CytoDyn.
Patients who were given Leronlimab — an antibody blocking CCR5 receptor which is expressed on tumor cells – with Carboplatin experienced a 300% increase in mean time to disease progression, as well as a 450% increase in 1-year survival.
Leronlimab (PRO 140) is administered via injection.
About the Trial
This phase 1b-2 study included 30 patients with mTNBC. In the first stage, patients were divided into 3 experimental cohorts:
In cohort A, patients received 350 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort B treated patients with 525 mg of Leronlimab weekly and Carboplatin every 3 weeks.
Cohort C treated patients with 700 mg of Leronlimab weekly and Carboplatin every 3 weeks.
The trial enrolled patients over 18 years of age who had expression of CCR5 on their cancer cells by immunohistochemistry, IHC, test.
“We are very excited about these preliminary results and are eager to discuss the next regulatory steps based on [these] data,” Scott Kelly, MD, chief medical officer of CytoDyns and chairman of the board said in a press release. “Based on Leronlimab’s mechanism of action, we believe these results may provide tangible hope for patients suffering from mTNBC, and potentially other forms of cancer.”
What is the current status of Leronlimab (PRO140) in Triple Negative Breast Cancer?
The FDA has granted a Fast-Track designation to Leronlimab (PRO140) for use in combination with Carboplatin for the treatment of patients with CCR5-positive metastatic Triple Negative Breast Cancer, TNBC.
Take home message
Patients with metastatic Triple Negative Breast Cancer, TNBC, being treated with Leronlimab and Carboplatin have experienced an increase in survival.
Talk to us so see if we can help you to actually get the most advanced treatment.
(0)
(0)